Systemic oncological treatments in patients with advanced pancreatic
cancer: A scoping review and evidence map.
Supportive Care in Cancer


Salazar J (1), Bracchiglione J (1,2), Acosta-Dighero R (3), Meza N (2), Meade A (1), Quintana MJ (1,6),
Requeijo C (1), Rodríguez-Grijalva G (1), Santero M (1), Selva A (4, 6), Solà I (1,5,6), Bonfill X (1,5,6),
Appropriateness of Systemic Oncological Treatments for Advanced Cancer (ASTAC) Research Group.

(1)      Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona,
Spain
(2)      Interdisciplinary Centre for Health Studies (CIESAL), Universidad de Valparaíso, Viña del Mar, Chile
(3)      Department of Physical Therapy, Faculty of Medicine, University of Chile, Santiago, Chile
(4)      Corporació Sanitària Parc Taulí, Sabadell, Spain
(5)      CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
(6)      Universitat Autònoma Barcelona, Barcelona, Spain.

Corresponding author: Xavier Bonfill Cosp, C/ Sant Antoni Maria Claret, 167, Pavelló 18, planta 0. 08025.
Barcelona, España. Teléfono: +34 93 553 78 14 Fax: +34 93 553 78 09. xbonfill@santpau.cat




                                                                                                                1
SEARCH STRATEGY FOR PUBMED

        #1     ("Gastrointestinal Neoplasms"[Mesh:NoExp] OR "Esophageal Neoplasms"[Mesh] OR
               "Stomach Neoplasms"[Mesh] OR "Liver Neoplasms"[Mesh] OR "Biliary Tract
               Neoplasms"[Mesh] OR "Pancreatic Neoplasms"[Mesh])

        #2     ((esophag*[Title] OR oesophag*[Title] OR stomach*[Title] OR gastric*[Title] OR
               gastroesophag*[Title] OR liver*[Title] OR hepatic*[Title] OR hepatocel*[Title] OR
               biliary tract*[Title] OR bile duct*[Title] OR gallbladder*[Title] OR gall bladder*[Title]
               OR    pancreas*[Title]   OR      pancreatic*[Title]       OR     gastrointestinal*[Title])    AND
               (cancer*[Title] OR carcinom*[Title] OR neoplasm*[Title] OR tumor*[Title] OR
               tumour*[Title] OR malignan*[Title] OR adenocar*[Title] OR oncolog*[Title]))

        #3     (#1 OR #2)

        #4     ("Palliative Care"[Mesh] OR "Terminal Care"[Mesh] OR "Neoplasm
               Metastasis"[Mesh])

        #5     (palliative*[Title/Abstract]    OR    end    of     life*[Title/Abstract]     OR     end     of
                        live*[Title/Abstract]         OR             terminal*[Title/Abstract]              OR
                        metasta*[Title/Abstract]     OR          BSC[Title/Abstract]       OR     supportive
                        care*[Title/Abstract]        OR               advanced*[Title/Abstract]             OR
                        unresect*[Title/Abstract]         OR       irresect*[Title/Abstract]                OR
                        nonresect*[Title/Abstract]         OR      non        resect*[Title/Abstract]       OR
                        inopera*[Title/Abstract]           OR         unopera*[Title/Abstract]              OR
                        nonopera*[Title/Abstract]         OR non opera*[Title/Abstract] OR non-
                        opera*[Title/Abstract] OR stage IV[Title/Abstract])

        #6     (#4 OR #5)

        #7     (#3 AND #6)

        #8     ("Antineoplastic Protocols"[Mesh] OR "Chemoradiotherapy"[Mesh] OR "Induction
               Chemotherapy"[Mesh] OR "Maintenance Chemotherapy"[Mesh] OR "Consolidation
               Chemotherapy"[Mesh])

        #9     (antineoplastic*[Title/Abstract]        OR           antineoplasic*[Title/Abstract]               OR
               chemotherap*[Title/Abstract]         OR           chemoradiotherap*[Title/Abstract]               OR
               radiochemotherap*[Title/Abstract]           OR          carboplatin*[Title/Abstract]              OR
               cisplatin*[Title/Abstract] OR fluorouracil*[Title/Abstract] OR 5-FU[Title/Abstract] OR
               capecitabine*[Title/Abstract]           OR             docetaxel*[Title/Abstract]                 OR
               epirucibin*[Title/Abstract]           OR              irinotecan*[Title/Abstract]                 OR
               oxaliplatin*[Title/Abstract]           OR             paclitaxel*[Title/Abstract]                 OR
               trifluridine*[Title/Abstract] OR tipiracil*[Title/Abstract])




                                                                                                                  2
#10   (#8 OR #9)

#11   ("Molecular Targeted Therapy"[Mesh] OR "Antibodies, Monoclonal"[Mesh] OR
      "Cancer Vaccines"[Mesh])

#12   (Target*[Title/Abstract]            OR               antibod*[Title/Abstract]               OR
      immunotherap*[Title/Abstract] OR vaccine[Title/Abstract] OR vaccines[Title/Abstract]
      OR vaccination[Title/Abstract] OR HER2[Title/Abstract] OR HER-2[Title/Abstract] OR
      egfr[Title/Abstract]   OR     VEGF*[Title/Abstract]         OR       HGF[Title/Abstract]    OR
      MET[Title/Abstract] OR claudin*[Title/Abstract] OR MMP
      9[Title/Abstract][JP1]      OR     tyrosine        kinase        inhibit*[Title/Abstract]   OR
      trastuzumab[Title/Abstract]          OR             bevacizumab[Title/Abstract]             OR
      rilotumumab[Title/Abstract]            OR           onartuzumab[Title/Abstract]             OR
      ramucirumab[Title/Abstract]             OR            cetuximab[Title/Abstract]             OR
      panitumumab[Title/Abstract]            OR           nimotuzumab[Title/Abstract]             OR
      claudiximab[Title/Abstract] OR apatinib[Title/Abstract] OR lapatinib[Title/Abstract]
      OR       regorafenib[Title/Abstract]          OR        everolimus[Title/Abstract]          OR
      nivolumab[Title/Abstract]          OR          pembrolizumab[Title/Abstract]                OR
      avelumab[Title/Abstract]            OR              durvalumab[Title/Abstract]              OR
      ipilimumab[Title/Abstract] OR checkpoint inhibit*[Title/Abstract])

#13   (#11 OR #12)

#14   (#10 OR #13)

#15   (#7 AND #14)

#16   (animals [mh] NOT humans [mh])

#17   #15 NOT #16




                                                                                                   3